JAK2 and myeloproliferative neoplasm: An activated mutant of Jak2, Jak2-V617F, is found in more than 90% of polycythemia vera and about 50% of essential thrombocythemia or primary myelofibrosis and is implicated in pathogenesis and progression of these myeloproliferative neoplasms [3], [4].